Skip to main content

Table 4 The relationship between clinical characteristics and cytotoxicity of the regimens combining chidamide with IDA in primary refractory or relapsed CD34+ AML cells

From: Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells

Characteristic Group Apoptotic cells (%)
Con. Chidamide IDA Chi + IDA P value
Status Refractory (n = 7) 25.86 ± 8.36 34.30 ± 11.07 53.84 ± 18.84 70.00 ± 13.96 0.732
  Relapse (n = 5) 26.20 ± 7.74 31.52 ± 7.47 49.21 ± 15.93 72.00 ± 7.64  
WBC >30 (n = 6) 27.54 ± 9.79 36.05 ± 11.21 58.28 ± 18.96 76.63 ± 9.60 0.016*
(×109/l) <30 (n = 6) 24.46 ± 5.50 30.24 ± 7.10 45.54 ± 13.60 65.00 ± 10.46  
Karyotype Non-complex (n = 8) 25.36 ± 9.57 31.61 ± 10.84 49.45 ± 16.28 68.62 ± 11.37 0.178
  Complex (n = 4) 27.30 ± 1.64 36.19 ± 5.89 56.83 ± 20.07 75.17 ± 11.50  
LDH Normal (n = 6) 24.77 ± 6.94 30.88 ± 7.39 50.48 ± 16.02 66.97 ± 9.98 0.221
  High (n = 6) 27.24 ± 8.94 35.41 ± 11.37 53.34 ± 19.49 74.65 ± 12.16  
Total   26.00 ± 7.74 33.14 ± 9.45 51.91 ± 17.08 70.81 ± 11.34 <0.01
  1. WBC white blood cell, LDH lactic dehydrogenase, IDA idarubicin, Con. control group, Chi chidamide